- Hepatitis B treatments and diagnostics are increasingly vital components of the Middle East and Africa’s public health systems, especially across both hospital and community-based care settings, due to growing infection awareness, improved access to testing, and advancements in antiviral therapies
- The escalating demand for effective Hepatitis B management is primarily fueled by government-led vaccination programs, rising HBV-HDV co-infection screening, and the increasing burden of chronic liver diseases, particularly among aging and high-risk populations
- Saudi Arabia dominated the Middle East and Africa hepatitis B infection market with the largest revenue share of 34.7% in 2024, characterized by comprehensive national immunization programs, early adoption of advanced diagnostic tools, and wide-scale HBV screening initiatives. The country has experienced a steady increase in treatment uptake, particularly among at-risk populations, supported by strong awareness campaigns and accessible public healthcare services
- U.A.E. is expected to be the fastest growing region in the Middle East and Africa Hepatitis B Infection market, driven by widespread implementation of hepatitis screening in employment and visa processes, high vaccination coverage, and access to modern healthcare facilities. Continuous R&D efforts and the country’s thriving medical tourism sector also support innovation and growth in HBV management
- The chronic hepatitis B segment dominated the Middle East and Africa hepatitis B infection market with a market share of 62.4% in 2024, attributed to the persistent and long-term nature of the disease, requiring ongoing antiviral therapy and surveillance, along with enhanced detection rates due to expanded public health screening programs
